{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T08:51:48Z","timestamp":1777452708929,"version":"3.51.4"},"reference-count":37,"publisher":"SAGE Publications","issue":"3","license":[{"start":{"date-parts":[[2016,4,1]],"date-time":"2016-04-01T00:00:00Z","timestamp":1459468800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Antiviral Therapy"],"published-print":{"date-parts":[[2017,4]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>HIV\u2013HCV-coinfected patients respond just as well to modern direct-acting antiviral HCV therapy as HCV-monoinfected patients. However, clinical data for all-oral HCV treatments are sparse in HIV\u2013HCV-coinfected patients with an advanced stage of liver cirrhosis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A subanalysis of efficacy and safety for a daclatasvir (DCV) and sofosbuvir (SOF) regimen, with or without ribavirin (RBV), was undertaken in HIV\u2013HCV-coinfected patients with advanced liver disease and no other treatment options enrolled into a European DCV compassionate use programme.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Fifty five HIV\u2013HCV (mostly genotypes 1, 3, 4) coinfected patients were treated with DCV+SOF with ( n=16) or without RBV ( n=39), mostly for 24 weeks. Patients were predominantly (95%) cirrhotic (50% were Child\u2013Pugh class B or C) and were receiving a wide range of antiretrovirals; 40% were injection drug users and 25% were receiving oral opioid substitution. Sustained virological response at post-treatment week 12 (SVR12) by modified intention-to-treat analysis ( n=52) was 92% overall (95% CI 81.5, 97.9), and was similar with (94% [95% CI 69.8, 99.8]) or without RBV (92% [95% CI 77.5, 98.2]). Only one patient relapsed (Child\u2013Pugh class B). The overall SVR12 rate after excluding non-virologi-cal failures ( n=49) was 98% (95% CI 89.1, 99.9). Four patients discontinued treatment for adverse events and one died during treatment (not treatment-related). No patient lost opioid maintenance or required a change of antiretrovirals due to drug\u2013drug interactions.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>DCV+SOF, with or without RBV, showed high SVR12 rates and was well tolerated in this real-world cohort of HIV\u2013HCV-coinfected patients with very advanced liver disease. ClinicalTrials.gov ID NCT02097966 (Study AI444-237).<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3851\/imp3108","type":"journal-article","created":{"date-parts":[[2016,11,15]],"date-time":"2016-11-15T06:52:16Z","timestamp":1479192736000},"page":"225-236","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":25,"title":["Daclatasvir plus Sofosbuvir, with or without Ribavirin, in Real-World Patients with HIV\u2013HCV Coinfection and Advanced Liver Disease"],"prefix":"10.1177","volume":"22","author":[{"given":"J\u00fcrgen K","family":"Rockstroh","sequence":"first","affiliation":[{"name":"Universit\u00e4tsklinikum Bonn, Bonn, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrick","family":"Ingiliz","sequence":"additional","affiliation":[{"name":"Medizinisches Infektiologiezentrum Berlin, Berlin, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J\u00f6rg","family":"Petersen","sequence":"additional","affiliation":[{"name":"IFI-Medizin GmbH and the Asklepios Klinik St Georg, Hamburg, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Markus","family":"Peck-Radosavljevic","sequence":"additional","affiliation":[{"name":"Medical University of Vienna, Vienna, Austria"},{"name":"Klinikum Klagenfurt am W\u00f6rthersee, Klagenfurt, Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tania M","family":"Welzel","sequence":"additional","affiliation":[{"name":"Universit\u00e4tsklinikum der Johann Wolfgang Goethe-Universit\u00e4t, Frankfurt, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marc","family":"Van der Valk","sequence":"additional","affiliation":[{"name":"Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yue","family":"Zhao","sequence":"additional","affiliation":[{"name":"Bristol-Myers Squibb, Global Biostatistics, Hopewell, NJ, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Jesus","family":"Jimenez-Exposito","sequence":"additional","affiliation":[{"name":"Bristol-Myers Squibb, Research and Development, Princeton, NJ, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefan","family":"Zeuzem","sequence":"additional","affiliation":[{"name":"Universit\u00e4tsklinikum der Johann Wolfgang Goethe-Universit\u00e4t, Frankfurt, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2016,4,1]]},"reference":[{"key":"bibr1-IMP3108","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(15)00485-5"},{"key":"bibr2-IMP3108","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0b013e318068d190"},{"key":"bibr3-IMP3108","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)60604-8"},{"key":"bibr4-IMP3108","doi-asserted-by":"publisher","DOI":"10.3851\/IMP1831"},{"key":"bibr5-IMP3108","doi-asserted-by":"publisher","DOI":"10.9778\/cmajo.20130009"},{"key":"bibr6-IMP3108","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa032653"},{"key":"bibr7-IMP3108","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa040842"},{"key":"bibr8-IMP3108","first-page":"16","volume":"9","author":"Gatti F.","year":"2007","journal-title":"AIDS Rev"},{"key":"bibr9-IMP3108","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2015.1328"},{"key":"bibr10-IMP3108","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1501315"},{"key":"bibr11-IMP3108","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1503153"},{"key":"bibr12-IMP3108","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2014.7734"},{"key":"bibr13-IMP3108","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0141164"},{"key":"bibr14-IMP3108","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofw105"},{"key":"bibr15-IMP3108","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(09)62041-9"},{"key":"bibr16-IMP3108","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-015-1890-3"},{"key":"bibr17-IMP3108","doi-asserted-by":"publisher","DOI":"10.1038\/nature08960"},{"key":"bibr18-IMP3108","doi-asserted-by":"publisher","DOI":"10.1021\/jm100863x"},{"key":"bibr19-IMP3108","doi-asserted-by":"publisher","DOI":"10.3851\/IMP2674"},{"key":"bibr20-IMP3108","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00478-15"},{"key":"bibr21-IMP3108","volume-title":"US Prescribing Information 2015.","author":"Sovaldi (sofosbuvir)."},{"key":"bibr22-IMP3108","unstructured":"American Association for the Study of Liver Diseases and the Infectious Diseases Society of America. Recommendations for testing, managing, and treating hepatitis C. (Accessed 9 May 2016.) Available from http:\/\/www.hcvguidelines.org."},{"key":"bibr23-IMP3108","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2015.03.025"},{"key":"bibr24-IMP3108","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/civ1222"},{"key":"bibr25-IMP3108","doi-asserted-by":"publisher","DOI":"10.1016\/0168-8510(90)90421-9"},{"key":"bibr26-IMP3108","doi-asserted-by":"publisher","DOI":"10.1016\/0168-8510(96)00822-6"},{"key":"bibr27-IMP3108","unstructured":"US Department of Health and Human Services, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Division of AIDS. Division of AIDS table for grading the severity of adult and pediatric adverse events, version 1.0. (Updated August 2009. Accessed 10 October 2016) Available from http:\/\/rsc.tech-res.com\/clinical-research-sites\/safety-reporting\/daids-grading-tables."},{"key":"bibr28-IMP3108","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2014.10.032"},{"key":"bibr29-IMP3108","doi-asserted-by":"publisher","DOI":"10.1097\/MOT.0000000000000199"},{"key":"bibr30-IMP3108","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2015.03.029"},{"key":"bibr31-IMP3108","unstructured":"Grebely J., Dore G.J., Altice F. C-EDGE CO-STAR: efficacy of elbasvir\/grazoprevir in HCV-infected persons who inject drugs receiving opioid agonist therapy.\n                      HepDART.\n                      6\u201310 December 2015, Wailea, HI, USA. Abstract 124."},{"key":"bibr32-IMP3108","volume-title":"US Prescribing Information 2016","author":"TECHNIVIE (ombitasvir, paritaprevir, and ritonavir)."},{"key":"bibr33-IMP3108","volume-title":"US Prescribing Information 2016","author":"VIEKIRA PAK (ombitasvir, paritaprevir, and ritonavir tablets; dasabuvir tablets)."},{"key":"bibr34-IMP3108","volume-title":"US Prescribing Information 2016","author":"EPCLUSA (sofosbuvir and velpatasvir)."},{"key":"bibr35-IMP3108","volume-title":"US Prescribing Information 2016.","author":"Olysio (simeprevir)."},{"key":"bibr36-IMP3108","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(12)61142-8"},{"issue":"1","key":"bibr37-IMP3108","first-page":"1004A","volume":"54","author":"Bifano M.","year":"2011","journal-title":"Hepatology"}],"container-title":["Antiviral Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.3851\/IMP3108","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.3851\/IMP3108","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T12:52:10Z","timestamp":1777380730000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.3851\/IMP3108"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,4,1]]},"references-count":37,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2017,4]]}},"alternative-id":["10.3851\/IMP3108"],"URL":"https:\/\/doi.org\/10.3851\/imp3108","relation":{},"ISSN":["1359-6535","2040-2058"],"issn-type":[{"value":"1359-6535","type":"print"},{"value":"2040-2058","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,4,1]]}}}